Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company’s scientific researchers, together with its joint research partners, Universities of Jaén and Granada.
published key data in a peer reviewed journal, Expert Opinion on Biological Therapy, confirming the anti-tumor potential of a mixture of two pancreatic proenzymes trypsinogen and chymotrypsinogen. Treatment with proenzymes sensitizes cancer stem cells (CSCs) which may allow standard treatment approaches, like chemotherapy and radiotherapy to be more effective. Expert Opinion on Biological Therapy is a peer-reviewed medical journal covering research on all aspects of biological therapies.
The article is the fifth scientific publication published on the effects of proenzymes in cancer and fourth published in a peer reviewed journal. The current research demonstrates that novel pancreatic proenzyme formulations exert the following effects on CSCs:
Decreases cell proliferation and migration;
Induces cell differentiation on CSCs to become benign;
Impairs angiogenesis (tumor blood vessel formation); and
Reduces the metastatic potential of CSCs.
“We continue to publish compelling scientific data confirming the effects of proenzymes against CSCs and its potential as a targeted therapy,” said Dr Julian Kenyon, Propanc’s Chief Scientific Officer, “There is currently significant interest in therapies that are not only more effective and less toxic, but critically, also support the immune function of patients. Given the current global pandemic situation, the risk of secondary infection in people afflicted with cancer undergoing chemotherapy of radiation is life threatening. This is yet another significant potential clinical application of proenzymes as a cancer treatment regimen.”
“It has been accepted in the medical community that pancreatic proenzymes exert significant effects on tissue repair inflammation and the immune system, but less understood in its role as an anti-cancer therapy, despite both phenomena being closely linked,” said Professor Macarena Perán, Department of Health Sciences, University of Jaén and Propanc’s Scientific Advisor. “Our research concludes that proenzymes as an adjuvant therapy in cancer has proved to be a successful strategy for reducing tumor size and improving the survival rate. These observations have tremendous potential clinical applications for late-stage cancer patients suffering from solid tumors. My team and I remain determined to assist the Propanc Team introducing this new approach to the medical and scientific community.”
About the University of Jaén:
The University of Jaén is among the Top 50 of the best young universities in the world according to THE (Times Higher Education). Likewise, the University of Jaén received the EFQM 500+ European Seal of Excellence, the highest level of recognition awarded by the Excellence in Management Club, as the official representative of the European Foundation for Quality Management (EFQM) in Spain. It also stands out in the field of computing, since the University of Jaén is among the 75 best universities in the world, according to Academic Ranking of World Universities (ARWU) 2017. The University of Jaén is repeatedly in the top 4% of universities worldwide, according to the Ranking Center for World University Rankings (CWUR), which annually collects the thousand best and most valued among the more than 25,000 existing universities. In addition, it is the fourth Spanish university that has obtained the highest score in the ranking of international student satisfaction, published by the STEXX International Studyportals Organization, in its 2016 version.
About the University of Granada:
The University of Granada is widely recognized internationally for its quality in higher education, teaching, research and outreach. National and international rankings reflect the University Granada’s position among the top universities in Spain and among the best in the world. In 2018, the University of Granada has further consolidated this dominant position – taking 278th place in the world and 3rd in Spain in the recently published Shanghai Academic Ranking of World Universities (ARWU 2018). Viewed from the perspective of its performance in specific academic subjects, the UGR has also set a new record, with a further 34 subjects taught at the University featuring in the 2018 ARWU — 12 more than in 2017. Furthermore, 5 of the University Granada’s subjects feature among the world top 100, marking another significant milestone.
